Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 33

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 33
---
POSAL.

Appendix 1 Invitation To the shareholders of NLS Pharmaceutics Ltd., Zurich, Switzerland Zurich, July 29, 2025 Invitation to the Extraordinary Shareholders’ Meeting of NLS Pharmaceutics Ltd., Zurich, Switzerland Dear Shareholder, The board of directors of NLS Pharmaceutics Ltd. (the “ Board of Directors”), with registered office at The Circle6, 8058 Zurich, Switzerland (the “ Company”), is pleased to invite you to the extraordinary shareholders’ meeting of the Company (the “ NLS Meeting”). The shareholders’ meeting will be held as follows:

| – Date:         |     | August 25, 2025                                                                                |
|:----------------|:----|:-----------------------------------------------------------------------------------------------|
| – Doors open:   |     | 15:45 (CEST)                                                                                   |
| – Meeting time: |     | 16:00 (CEST)                                                                                   |
| – Place:        |     | At the premises of Baker McKenzie Switzerland AG, Holbeinstrasse 30, 8034 Zurich, Switzerland. |

The agenda items to be voted on, the voting instructions and the appendices mentioned herein are provided below: The Board of Directors reserves the right, for important reasons in the interest of the Company, to withdraw all subsequent proposals should any agenda item be rejected by the shareholders. In this case, none of the agenda items would be put to a vote. The agenda items and proposals of the Board of Directors are as follows: 1.Advisory vote: Approval of Merger Agreement Explanation:The Company entered into a merger agreement with Kadimastem Ltd. (“ Kadimastem”) on November 4, 2024 (“ Merger Agreement”) as announced and filed with the United States Securities and Exchange Commission on November 4 and 5, 2024. Proposal:The Board of Directors proposes that the Merger Agreement be approved on an advisory basis. 2.Par Value Reduction, Reverse Split and Contribution in Kind Explanation:As per the Merger Agreement, (i) NLS Pharmaceutics (Israel) Ltd., an Israeli company and a wholly owned subsidiary of the Company, is intended to merge with and into Kadimastem, with Kadimastem as the surviving company (the “ Merger”), and (ii) at the effective time of the Merger (the “Effective Time”), each issued and outstanding ordinary share of Kadimastem, with no par value (each, a “ Kadimastem